VC firms take part in €10m series-C for Themis

GHIF led the round and AWS Gründerfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences also took park.

The proceeds of the financing will be used to continue developing vaccines against chikungunya, a mosquito-borne virus, and other viruses.

Glenn Rockman, a partner at GHIF, will join the Themis supervisory board as part of the deal.

GHIF is a social impact investment fund structured by JP Morgan and the Bill & Melinda Gates Foundation. It finances the development of drugs, vaccines and diagnostics for diseases that disproportionately burden low-income populations.

Previous funding
Ventech led a €5m series-A funding round for Themis in May 2011. The investor returned in November 2016 to take part in a €10m series-B along with AWS Gründerfonds, Omnes Capital and Wellington Partners.

Company
Vienna-based Themis Bioscience was founded in 2009 and is a specialist developer of vaccines for emerging infectious diseases. The company has developed vaccine products for dengue and chikungunya fevers and is working on zika, respiratory syncytial virus (RSV), norovirus and cytomegalovirus, as well as other applications of immune system activation. The products are based on a new vaccine vector technology, developed by the Institut Pasteur in Paris with which Themis collaborates.

People
Themis – Erich Tauber (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Wellington Partners
• Ventech
• Omnes Capital